Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695139 | 0.90 | PLA2G2A (0.51) | PLA2G2APLA2G10 | |
| SCHEMBL8575181 | 0.87 | PLA2G2A (0.46) | PLA2G2APLA2G10 | |
| SCHEMBL6129602 | 0.86 | PLA2G2A (0.41) | PLA2G2APLA2G10 | |
| SCHEMBL6129642 | 0.86 | PLA2G2A (0.41) | PLA2G2APLA2G10 | |
| SCHEMBL29862552 | 0.86 | PLA2G2A (0.54) | PLA2G2APLA2G10 | |
| SCHEMBL818166 | 0.86 | PLA2G2A (0.54) | PLA2G2APLA2G10 | |
| SCHEMBL29862616 | 0.85 | PLA2G2A (0.52) | PLA2G2APLA2G10 | |
| SCHEMBL818181 | 0.85 | PLA2G2A (0.52) | PLA2G2APLA2G10 | |
| SCHEMBL6535821 | 0.85 | HTR6 (0.40) | PLA2G2APLA2G10 | |
| SCHEMBL818168 | 0.85 | PLA2G2A (0.44) | PLA2G2APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | claimed |
| JP-2004503586-A | — | — | 2004-02-05 | — | — | JP | claimed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | claimed |
| EP-1259260-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2002-11-27 | — | — | EP | claimed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| JP-2001522884-A | — | — | 2001-11-20 | — | — | JP | claimed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | claimed |
| EP-1043991-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-10-18 | — | — | EP | claimed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | claimed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | claimed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | claimed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | claimed |
| EP-1043991-A4 | TREATMENT FOR ALZHEIMER'S DISEASE | LILLY CO ELI (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1011670-A4 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | LILLY CO ELI (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | disclosed |